Covance Inc.  

(Public, NYSE:CVD)   Watch this stock  
Find more results for Debora F. Keller
106.53
-0.54 (-0.50%)
Jan 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 106.28 - 106.72
52 week 73.57 - 107.35
Open 106.63
Vol / Avg. 227,160.00/745,692.00
Mkt cap 6.06B
P/E 34.03
Div/yield     -
EPS 3.13
Shares 56.58M
Beta 0.94
Inst. own 90%
Feb 18, 2015
Covance Inc Extraordinary Shareholders Meeting - 8:00AM EST - Add to calendar
Feb 2, 2015
Q4 2014 Covance Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 12, 2014
Covance Inc at Credit Suisse Healthcare Conference
Nov 3, 2014
Q3 2014 Covance Inc Earnings Release
Nov 3, 2014
Laboratory Corporation of America Holdings to Acquire Covance Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 9.84% 6.91%
Operating margin 13.41% 8.37%
EBITD margin - 15.31%
Return on average assets 10.44% 7.40%
Return on average equity 16.22% 12.48%
Employees 12,501 -
CDP Score - -

Address

210 Carnegie Center
PRINCETON, NJ 08540
United States - Map
+1-609-4524440 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Officers and directors

Joseph L. Herring Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Alison A. Cornell Chief Financial Officer, Vice President
Age: 51
Bio & Compensation  - Reuters
Richard F. Cimino Executive Vice President, Group President - Clinical Development
Age: 54
Bio & Compensation  - Reuters
Deborah L. Keller Tanner Executive Vice President, Group President - Research and Development Laboratories
Age: 51
Bio & Compensation  - Reuters
William E. Klitgaard Corporate Senior Vice President, Chief Information Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James W. Lovett Esq. Corporate Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
John E. Watson Corporate Senior Vice President, Chief Commercial Officer, President - Strategic Partnering
Age: 54
Bio & Compensation  - Reuters
Brian H. Nutt Principal Accounting Officer, Senior Director of External Reporting
Age: 44
Bio & Compensation  - Reuters
Gary E. Costley Ph.D. Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Robert L. Barchi M.D., Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters